key: cord-0785684-x2tz0q2b
authors: Munoz-Rivas, N.; Aibar, J.; Gabara-Xanco, C.; Trueba-Vicente, A.; Urbelz-Perez, A.; Gomez-Del Olmo, V.; Demelo-Rodriguez, P.; Rivera-Gallego, A.; Bosch-Nicolau, P.; Perez-Pinar, M.; Rios-Prego, M.; Madridano-Cobo, O.; Ramos-Alonso, L.; Alonso-Carrillo, J.; Francisco-Albelsa, I.; Marti-Saez, E.; Maestre-Peiro, A.; Mendez-Bailon, M.; Hernandez-Rivas, J. A.; Torres-Macho, J.
title: Optimal thromboprophylaxis strategies in non-critically ill patients with COVID-19 pneumonia. The PROTHROMCOVID Randomized Controlled Trial.
date: 2022-05-05
journal: nan
DOI: 10.1101/2022.05.03.22274594
sha: b9e123ba70881b67968d97c6759b98b8931f0ede
doc_id: 785684
cord_uid: x2tz0q2b

Background : Hospitalized patients with COVID-19 are at increased risk for thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. Objective: To evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. Design, setting, and participants : Randomized controlled, multicenter trial (PROTHROMCOVID) enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Interventions: Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) doses of tinzaparin during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. Measurements: The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Results : Of the 311 subjects randomized, 300 were included in the analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]. The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (P= 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Conclusions: In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to increase benefit regarding the likelihood of thrombotic event, non-invasive ventilation or high-flow oxygen, or death. Trial Registration ClinicalTrials.gov Identifier (NCT04730856). Funding: This independent research initiative was supported by Leo-Pharma; Tinzaparin was provided by Leo Pharma.

Severe, acute, respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection can cause different clinical manifestations, ranging from mild to very severe symptomatology, with significant morbidity and mortality, principally associated with bilateral pneumonia that can cause acute respiratory distress syndrome (ARSD). More than 6 million people have died since the first reports in late 2019 in Wuhan, China and it is estimated that more than 450 million people have been infected with COVID-19 to date. Recent research estimates more than that 18 million people died worldwide because of the COVID-19 pandemic (as measured by excess mortality) over that period (1) . Since the first wave of the SARS-CoV-2 pandemic, the increase in systemic thrombosis in hospitalized patients was evident (2) , particularly in critical care units worldwide (3) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2022. ;  https://doi.org/10.1101/2022.05.03.22274594 doi: medRxiv preprint been published to date, focusing on anticoagulation intensity in patients admitted for COVID-19 (7) . While the results have been more robust against higher than usual prophylactic doses (8) in the critically ill patients (9) , uncertainty persists as to optimal LMWH doses in non-critical cases. Most trials have evaluated standard prophylactic LMWH dose strategies versus therapeutic doses or other oral anticoagulants, with contradictory results (10)(11).

The PROTHROMCOVID multicenter clinical trial was carried out to evaluate the efficacy of tinzaparin treatment at different doses (prophylactic, intermediate, and therapeutic) in patients with COVID-19 pneumonia to probe the endpoints of death, need for mechanical ventilation and venous or arterial thrombosis within 30 days following randomization. This trial also examined the safety of tinzaparin at different doses in relation to developing complications of both major and minor bleeding.

The PROTHROMCOVID study (NCT04730856) is a randomized, open-label, multicenter, controlled study in hospitalized patients with COVID-19 pneumonia, conducted in conventional hospital wards in 18 academic hospitals in Spain. This investigator-initiated clinical trial enrolled individuals with COVID-19 pneumonia who were hospitalized from February 1st, 2021 to September 30th, 2021.

Adults with a body weight of 50-100 kg who required admission to a conventional (noncritical) hospital ward due to COVID-19 pneumonia were included if they also met any of the following criteria: a) baseline oxygen saturation ≤94%, b) D-dimer > 1000 µg/L, c) C Reactive Protein (CRP) > 150 mg/L, or d) interleukin-6 (IL6) > 40 pg/mL). The main . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.05.03.22274594 doi: medRxiv preprint exclusion criteria were: a) need for full-dose anticoagulant therapy, b) active bleeding or situations prone to bleeding, c) glomerular filtration rate < 30 ml/min/1.73 m 2 , d) platelet count<80 x 10 9 /L, e) previous heparin-induced thrombocytopenia, and f) hypersensitivity/intolerance to heparins. The study design and full list of eligibility and exclusion criteria are provided in the supplementary material (Supplementary file Table   S1 and Table S2 )

Patients were screened at hospitalization and randomized at a ratio of 1:1:1 by means of a central, electronic, automated system with permuted blocks of 6. Neither participants nor investigators were blinded as to group assignment. Subjects were stratified by age, sex, and presence of high blood pressure. Those who were assigned to the control group received standard prophylaxis with subcutaneous (sc) tinzaparin 4500 IU once daily. The experimental group received tinzaparin 100 IU/kg once daily (intermediate dose group) or 175 IU/kg once daily (therapeutic dose group). The assigned treatments remained the same throughout hospitalization. After discharge, all patients received tinzaparin 4500 IU/day subcutaneously for seven days, after which thromboprophylaxis was maintained at the discretion of the investigator. If intensive care unit (ICU) admission was required, the patients could remain with the study drug or not, according to local practices. Except for the assigned anticoagulation therapy, all other clinical care was provided as per local protocols.

Demographic characteristics, comorbidities, medications, and laboratory evaluations were recorded at randomization. The primary efficacy outcome was a composite endpoint of death, need for invasive mechanical ventilation (IMV), non-invasive ventilatation (NIV) or high flow oxygen with nasal cannula (HFNC), and venous or arterial thrombosis . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.05.03.22274594 doi: medRxiv preprint within 30 days after randomization. Secondary efficacy variables were the same endpoints at 30 and 90 days, progression to ARDS, and length of hospital stay. Safety outcomes were major bleeding and clinically relevant non-major bleeding, as defined by the International Society on Thrombosis and Hemostasis (ISTH) (12) . Outcomes were adjudicated locally by the investigators based on objectively confirmed diagnostic tests, laboratory results, and other objective data from the clinical record.

Considering the main objective, the incidence in the control group was expected to be 24% and 12% in groups 2 and 3. The sample size was calculated from a proportion of a 13% reduction in thrombosis in the control group and a difference of 5% compared to treatment groups.

Accepting an alpha risk of 0.025 and a beta risk of <0.2 in a bilateral contrast, statistically significant differences could be detected with 200 patients per group. The study protocol included an interim analysis when 50% of the target population had been included. An interim analysis was scheduled to be performed after 300 patients were included. The trial could be stopped for: (1) superiority; (2) futility with regard to the primary endpoint; or (3) safety reasons. Following the results of this interim analysis presented in this article, the Scientific Committee decided to prematurely halt the clinical trial, based on the futility analysis and the drop in recruitment at the end of fifth wave.

Categorical variables were expressed as frequencies and percentages, and quantitative variables as mean ± standard deviation (SD) or median and interquartile range (IQR), relative to distribution. The Saphiro-Wilk test was used to examine the normality of the distributions of samples of <30 and the Kolmogorov-Smirnoff test was applied in the other cases. For intergroup statistical analysis, chi-square or Fisher's exact test were used for categorical variables and unpaired Student's t test or Mann-Whitney test for . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2022.

From February 1 st , 2021 to September 30 th , 2021, 311 patients were enrolled coinciding with the third to the fifth pandemic wave in Spain. Eleven patients withdrew informed consent prior to initiating treatment, resulting in a total of 300 patients in the analysis.

Among these patients, the intention-to-treat, per-protocol and safety populations were equally constituted, with no major protocol deviations detected and all treatment doses . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure S2 ).

In terms of safety, the rate of bleeding was very low in all 3 groups. No major bleeding was reported and 7 patients (6.6%) in group A, 3 participants (3.2%) in group B, and 3 patients (2.9%) in group C suffered non-major bleeding, with no significant differences across groups (P=0.38). (Supplementary file Table S3) Secondary endpoints: Secondary efficacy outcomes are displayed in Figure 2 The Wilkoxon paired signs test showed no differences in progression between groups.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Similarly to our results, the RAPID trial determined that there was no significant difference between therapeutic or prophylactic strategies in non-critically ill patients admitted for COVID-19 in the combined endpoint of death, mechanical ventilation, or ICU admission (13) . Moreover, the BEMICOP clinical trial, a small study conducted with bemiparin, did not find any differences in the primary endpoint between cases randomized . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.05.03.22274594 doi: medRxiv preprint to therapeutic doses in comparison with prophylactic doses (14) . In contrast, the results of REMAP-CAP, ACTIV-4a, and ATTAC multi-platform collaborative trials support an early strategy of full-dose anticoagulant doses of heparin in non-critically ill subjects by demonstrating an increased in organ-free support days (98.6% vs 95.0%, respectively) in comparison to standard doses of LMWH thromboprophylaxis (10) . Despite being the clinical trial that has included the largest number of patients, statistical significance was barely reached and there were no statistically differences in other outcomes among groups, including thrombosis, survival to hospital discharge and bleeding. Besides, the percentage of patients who received intermediate doses in the prophylaxis group was high (26%), which may have biased the results (15). The HEPCOVID trial, with a dose design similar to PROTHROMCOVID trial, showed a decrease in events, thromboembolism and death in the therapeutic-dose LMWH in hospitalized but not in ICU patients, with no differences at the intermediate-dose (16) . It should be noted that the HEPCOVID trial was carried out in May 2020, during the first wave, with a higher percentage of events than the one observed in our trial and in those conducted in later stages of the pandemic. Similarly, the incidence of thrombosis recorded during the first wave (19) in our own setting was higher than data collected during the second wave. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2022. LMWH for young people and adults with COVID-19 who need low-flow oxygen and who do not have an increased bleeding risk (22) .

In terms of safety, the risk of bleeding tends to be higher in most of the studies in which the anticoagulation strategy is more intense (23) . In multiplatform trials, the risk of major bleeding was 1.8% in controls receiving standard prophylaxis versus 3.7% in those receiving therapeutic doses (10). The PROTHROMCOVID study participants had no major bleeding events, perhaps because of the smaller sample size than in the collaborative trials, the characteristics of the included population or the type of heparin used. (6) We believe our safety data to be of the utmost importance because it does not appear from our results that the option of anticoagulation or intermediate doses generates an increased risk of unsafe major bleeding in the patient profile suggested by the NICE recommendation.

Our study has certain limitations; for instance, neither investigators nor patients were blinded. The main weakness of our results, however, is not having reached the estimated sample size of 600 patients, given that the researchers chose to interrupt the study on September 2021 because the results of the interim analysis. It revealed a very low absolute number of events in each arm and the futility analysis showed that it was unlikely that significant differences could have been reached with the complete sample.

These results should not be extrapolated to other more severe hospitalized patients with COVID-19.

The strengths of our study include the low number of withdrawals of informed consent by patients, the very early use of tinzaparin in all three arms of the study, which may have influenced the favorable efficacy and safety outcomes and the fact that the three strategies of anticoagulation have been tested with the same LMWH. Similarly, this was a . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.05.03.22274594 doi: medRxiv preprint multicenter study conducted in academic and general care centers. Furthermore, the study was carried out during a phase of the pandemic were the incidence of thrombosis and mortality were lower than before; thus, the findings of our study might be more applicable to future waves of the pandemic, which are expected to be milder due to generalized immunization and better treatment options. (24) . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.05.03.22274594 doi: medRxiv preprint data managers who contributed to PROTHROMCOVID clinical trial. We would also like to thank the patients and their families who participated in this study during the difficult times of the COVID-19 pandemic. The authors thank Leo Pharma for funding and support. The authors would also like to express a special thanks to Angélica Martin and Almudena Sánchez from S&H Medical.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2022. ; https://doi.org/10.1101/2022.05.03.22274594 doi: medRxiv preprint

Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality

Pulmonary Thrombosis and Thromboembolism in COVID-19

Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)

High Prevalence of Deep Vein Thrombosis in Mechanically Ventilated

COVID-19 coagulopathy: An indepth analysis of the coagulation system

Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients

Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in nonsurgical patients: communication from the SSC of the ISTH

Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG -RAPID Trial): A structured summary of a study protocol for a randomised controlled trial

Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

Platform Trials -Beware the Noncomparable Control Group

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial

Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study

Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

London: National Institute for Health and Care Excellence (NICE)

National Institute for Health and Care Excellence: Clinical Guidelines)

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Clinical characteristics of patients hospitalized with COVID-19

We are indebted to the physicians, nurses, study coordinators, and